Publikationen in Zusammenarbeit mit Forschern von Hospital Universitario de Puerto Real (29)

2024

  1. Real-World Clinical Experience of Dupilumab in the Treatment of Chronic Palmo-Plantar Eczema in Patients with Moderate-Severe Atopic Dermatitis: 52-Week Follow-Up

    Dermatitis, Vol. 35, pp. S55-S61

  2. [Translated article] Efficacy and Pharmacoeconomic Analysis in Real Clinical Practice Conditions of Patients with Plaque Psoriasis Treated with Guselkumab: A Retrospective Multicenter Study

    Actas Dermo-Sifiliograficas

2023

  1. Brodalumab: Efficacy, safety, and survival in mid-term (52 weeks) on real clinical practice in Andalucia, Spain

    International Journal of Dermatology, Vol. 62, Núm. 5, pp. 700-706

  2. Clinical Approach to Patients with Moderate-to-Severe Atopic Dermatitis: A Spanish Delphi Consensus

    Acta Dermato-Venereologica, Vol. 103

  3. Efficacy and Pharmacoeconomic Analysis in Real Clinical Practice Conditions of Patients with Plaque Psoriasis Treated with Guselkumab: A Retrospective Multicenter Study

    Actas Dermo-Sifiliograficas

  4. Treatment of severe atopic dermatitis with tralokinumab in clinical practice: short-term effectiveness and safety results

    Clinical and experimental dermatology, Vol. 48, Núm. 9, pp. 991-997

  5. Upadacitinib for moderate to severe atopic dermatitis

    Immunotherapy, Vol. 15, Núm. 11, pp. 799-808

  6. Updated Review on Treatment of Atopic Dermatitis

    Journal of Investigational Allergology and Clinical Immunology, Vol. 33, Núm. 3, pp. 158-167

2022

  1. Atopic Dermatitis: Background, Objectives and Future Perspectives (Superresponders)

    Life

  2. Effectiveness, survival and safety of guselkumab attending to basal characteristics in moderate-to-severe psoriatic patients: A cohort study

    F1000Research, Vol. 11

  3. Guselkumab as a switching strategy after anti-TNFα, anti-IL17, or anti-IL12/23 therapies in moderate-to-severe psoriasis

    Dermatologic Therapy, Vol. 35, Núm. 10

  4. Guselkumab dosing interval optimization in adult patients with moderate-to-severe psoriasis switching from ustekinumab

    Dermatologic Therapy, Vol. 35, Núm. 11

  5. Long-Term Effectiveness and Safety of Biologic and Small Molecule Drugs for Moderate to Severe Atopic Dermatitis: A Systematic Review

    Life, Vol. 12, Núm. 8

  6. Super responders to guselkumab treatment in moderate-to-severe psoriasis: a real clinical practice pilot series

    International Journal of Dermatology, Vol. 61, Núm. 8, pp. 1029-1033

  7. Validation of a Questionnaire to Assess the Perception of Women with Atopic Dermatitis in Family Planning

    International journal of environmental research and public health, Vol. 19, Núm. 17

2021

  1. 104-week safety and effectiveness of dupilumab in the treatment of severe atopic dermatitis. The experience of 5 reference dermatology units in Spain

    Anais Brasileiros de Dermatologia, Vol. 96, Núm. 6, pp. 787-790

  2. Drug survival of systemic and biological treatments for moderate-to-severe atopic dermatitis in adults: a multicentre retrospective observational study

    British Journal of Dermatology

  3. Risankizumab: A pilot study of short-term effectiveness and safety in real clinical practice

    Dermatologic Therapy

  4. Secukinumab: Drug Survival in Clinical Practice Settings

    Actas Dermo-Sifiliograficas, Vol. 112, Núm. 4, pp. 361-364

  5. Short-term effectiveness and safety of biologics and small molecule drugs for moderate to severe atopic dermatitis: A systematic review and network meta-analysis

    Life, Vol. 11, Núm. 9